CLL1-CD33 cCART cell therapy / iCell Gene Therap - LARVOL DELTA

[VIRTUAL] FIRST-IN-HUMAN CLL1-CD33 COMPOUND CAR (CCAR) T CELL THERAPY IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (EHA 2020) - P1 | "All patients received conditioning of fludarabine and cyclophosphamide with doses of 30 mg/m2/d and 300 mg/m2/d respectively. CLL1-CD33 cCAR may provide a platform of reduced intensity conditioning or nonmyeloablative conditioning HSCT for treating AML and other myeloid malignancies. A Phase I clinical trial for CLL1-CD33 cCAR is underway."

IO biomarker • P1 data • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Dermatology • Hematological Disorders • Hematological Malignancies • Hemophilia • Immunology • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: iCell Gene Therapeutics; Trial completion date: Sep 2020 ➔ Sep 2022; Trial primary completion date: Sep 2020 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Oncology